What we're reading, February 10, 2016: 2 companies change how consumers purchase medicines online; CMS memo reveals the government is mulling changes to Medicare reimbursement; and Johns Hopkins will transplant HIV-positive organs to HIV-positive recipients.
Transparency is often cited as one of the best ways lower drug prices, and now 2 companies are pulling back the curtain to change how consumers purchase medicines. In a new article, The New York Times highlighted GoodRx, which collects drug prices and connects consumers with coupons, and Blink Health, which allows consumers to purchase drugs online and pick them up at nearly any pharmacy. The price quotes on these sites are for generic drugs, but they cannot help much with brand-name drugs.
A new memo from CMS has revealed that there may be changes coming for how Medicare pays physicians. However, the document has since been taken down from CMS’ website, and its release called “premature,” reported Bloomberg Business. According to the memo, a new payment system would allow reimbursement to doctors for the drugs they administer to vary by geographic location.
Johns Hopkins will become the first hospital in the United States to transplant organs from HIV-positive donors to HIV-positive recipients. Until recently, such use of organs from HIV-positive individuals was illegal in the US, but South Africa has been allowing these transplants for several years with positive outcomes, according to The Washington Post. The US passed a law in late 2013 legalizing the use of HIV-positive organs for HIV-positive recipients.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More